Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Fine

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Crohn'S & Colitis 360|June 1, 2026
Advanced therapy treatment patterns in moderate-to-severe ulcerative colitis: a long-term retrospective claims analysisParambir S Dulai, Christopher J Rabbat, Ian Nason, et al.
Cardiology and Therapy|March 1, 2022
Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database StudyAnjali T Owens, Megan B Sutton, Wei Gao, et al.
The American Journal of Cardiology|January 29, 2023
Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United StatesNihar R Desai, Megan B Sutton, Jipan Xie, et al.
Investigative Ophthalmology & Visual Science|February 2, 2011
Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degenerationPeggy Orr, Anne M Rentz, Mary Kay Margolis, et al.
JACC. Heart Failure|July 28, 2022
Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic CardiomyopathyMichael Nassif, Jennifer T Fine, Chantal Dolan, et al.
Investigative Ophthalmology & Visual Science|December 5, 2012
Author response: Validation of the National Eye Institute Visual Function Questionnaire-25 (NEIVFQ-25) in age-related macular degenerationPeggy Orr, Anne M Rentz, Mary Kay Margolis, et al.
American Heart Journal|October 31, 2001
Advanced coronary artery disease: Appropriate end points for trials of novel therapiesD E Kandzari, L C Lam, E L Eisenstein, et al.
Journal of Medical Economics|September 8, 2021
Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United StatesSneha S Jain, Sophia S Li, Jipan Xie, et al.
Lancet (London, England)|May 18, 2021
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trialJohn A Spertus, Jennifer T Fine, Perry Elliott, et al.
Journal of Cardiac Failure|June 7, 2026
Impact of Mavacamten on Disease-Related Symptoms in Patients With Obstructive Hypertrophic Cardiomyopathy: HCMSQ Outcomes in EXPLORER-HCMSara Saberi, Srihari S Naidu, Iacopo Olivotto, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Crohn'S & Colitis 360|June 1, 2026
Advanced therapy treatment patterns in moderate-to-severe ulcerative colitis: a long-term retrospective claims analysisParambir S Dulai, Christopher J Rabbat, Ian Nason, et al.
Cardiology and Therapy|March 1, 2022
Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database StudyAnjali T Owens, Megan B Sutton, Wei Gao, et al.
The American Journal of Cardiology|January 29, 2023
Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United StatesNihar R Desai, Megan B Sutton, Jipan Xie, et al.
Investigative Ophthalmology & Visual Science|February 2, 2011
Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degenerationPeggy Orr, Anne M Rentz, Mary Kay Margolis, et al.
JACC. Heart Failure|July 28, 2022
Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic CardiomyopathyMichael Nassif, Jennifer T Fine, Chantal Dolan, et al.
Investigative Ophthalmology & Visual Science|December 5, 2012
Author response: Validation of the National Eye Institute Visual Function Questionnaire-25 (NEIVFQ-25) in age-related macular degenerationPeggy Orr, Anne M Rentz, Mary Kay Margolis, et al.
American Heart Journal|October 31, 2001
Advanced coronary artery disease: Appropriate end points for trials of novel therapiesD E Kandzari, L C Lam, E L Eisenstein, et al.
Journal of Medical Economics|September 8, 2021
Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United StatesSneha S Jain, Sophia S Li, Jipan Xie, et al.
Lancet (London, England)|May 18, 2021
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trialJohn A Spertus, Jennifer T Fine, Perry Elliott, et al.
Journal of Cardiac Failure|June 7, 2026
Impact of Mavacamten on Disease-Related Symptoms in Patients With Obstructive Hypertrophic Cardiomyopathy: HCMSQ Outcomes in EXPLORER-HCMSara Saberi, Srihari S Naidu, Iacopo Olivotto, et al.
Pageof 5